SCHEMBL6097612

SCHEMBL6097612

COC1=C(OC)C(=O)C(Cc2cccc(C(=O)Nc3ccc(C(F)(F)F)cc3)c2OC(C)=O)=C(C)C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 7/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
PTGS1 P23219 1/20 0.40
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
GMNN O75496 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
HTR1A P08908 1/20 0.38
THRB P10828 1/20 0.38
PIM1 P11309 1/20 0.38
CYP2C9 P11712 1/20 0.38
MAOA P21397 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2A P28223 1/20 0.38
AGTR1 P30556 1/20 0.38
CCKBR P32239 1/20 0.38
MC4R P32245 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095316 0.89 NPC1 (0.46) NPC1RAB9ALMNACYP1A2CYP3A4
SCHEMBL6097209 0.89 RXFP1 (0.42) RXFP1SMN1; SMN2NPC1RAB9ATHRB
SCHEMBL6097419 0.88 P2RX1 (0.46) RXFP1SMN1; SMN2PTGS1NPC1RAB9A
SCHEMBL5860301 0.82 SMO (0.44) RXFP1SMN1; SMN2KDR
SCHEMBL6095529 0.82 POLB (0.53) SMN1; SMN2NPC1RAB9A
SCHEMBL6094093 0.82 MAPT (0.47) SMN1; SMN2NPC1RAB9ALMNATP53
SCHEMBL6096112 0.81 PPARA (0.50) LMNACYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL6096506 0.79 KDM4E (0.50) PTGS1LMNACYP1A2CYP3A4THRB
SCHEMBL6096251 0.78 ALDH1A1 (0.41) SMN1; SMN2NPC1RAB9ALMNATP53
SCHEMBL6095885 0.77 TMPRSS4 (0.50) SMN1; SMN2PTGS1P2RX1KDRAVPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064124-B2 NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2006-06-20 US claimed
US-7064124-B2 NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2006-06-20 US disclosed
US-20040122244-A1 Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2004-06-24 US disclosed
EP-1314712-A1 NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT Daiichi Suntory Pharma Co., Ltd. (JP) 2003-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122244-A1 Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient NFKBIA, NFKB1, IKBKB RXFP1 4462/4885SMN1; SMN2 4307/4885PTGS1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.